BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Tremelimumab readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Tremelimumab\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT02962063-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tremelimumab: Phase 1/2 readout est. (NCT02962063)
DESCRIPTION:Tremelimumab\, phase 1/2.\nStudy: Durvalumab\, an Anti-PDLI Ant
 ibody\, and Tremelimumab\, an Anti-CTLA4 Antibody\, and Chemoradiation Bef
 ore Surgery for Esophageal Cancer\nEstimated primary completion: November 
 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/tremelimumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT029620
 63
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03158064-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT03158064)
DESCRIPTION:Tremelimumab\, phase 2.\nStudy: Evaluating Immune Therapy\, Dur
 avalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tu
 mors\nEstimated primary completion: November 2026. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT03158064
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06058663-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tremelimumab: Phase 1 readout est. (NCT06058663)
DESCRIPTION:Tremelimumab\, phase 1.\nStudy: Radioembolization With Tremelim
 umab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic 
 Intrahepatic Cholangiocarcinoma\nEstimated primary completion: 30 November
  2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/tremelimumab#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06058
 663
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07081633-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT07081633)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Durv
 alumab and Tremelimumab With Lenvatinib as First-line Treatment in Patient
 s With Unresectable Hepatocellular Carcinoma\nEstimated primary completion
 : 30 November 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/t
 remelimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07081633
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05000710-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT05000710)
DESCRIPTION:Tremelimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Co
 ncomitant Radiotherapy\, Tremelimumab & Durvalumab for Advanced NSCLC Pati
 ents Progressing on First-line Immunotherapy\nEstimated primary completion
 : December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trem
 elimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05000710
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03965468-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT03965468)
DESCRIPTION:Tremelimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Im
 munotherapy\, Chemotherapy\, Radiotherapy and Surgery for Synchronous Olig
 o-metastatic NSCLC\nEstimated primary completion: December 2026. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/tremelimumab#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT03965468
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04585490-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tremelimumab: Phase 3 readout est. (NCT04585490)
DESCRIPTION:Tremelimumab\, phase 3\, Non-Small Cell Lung Cancer.\nStudy: Ad
 aptive ctDNA-Based Personalization of Treatment During Consolidation Thera
 py in NSCLC\nEstimated primary completion: December 2026. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT04585490
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03606967-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT03606967)
DESCRIPTION:Tremelimumab\, phase 2.\nStudy: Testing the Addition of an Indi
 vidualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Pati
 ents With Metastatic Triple Negative Breast Cancer\nEstimated primary comp
 letion: 30 December 2026. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/tremelimumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT03606967
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05844046-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT05844046)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Sequ
 ential or Up-front Triple Treatment With Durvalumab\, Tremelimumab and Bev
 acizumab for Non-resectable Hepatocellular Carcinoma (HCC) Patients\nEstim
 ated primary completion: 31 December 2026. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT05844046
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03937830-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT03937830)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Comb
 ined Treatment of Durvalumab\, Bevacizumab\, Tremelimumab and Transarteria
 l Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Bi
 liary Tract Carcinoma\nEstimated primary completion: 31 December 2026. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tremelimumab#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT03937830
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06698250-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT06698250)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Zanz
 alintinib (XL-092) Plus Durvalumab and Tremelimumab in Unresectable Hepato
 cellular Carcinoma (ZENOBIA)\nEstimated primary completion: 31 December 20
 26. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/tremelimumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06698250
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06824363-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tremelimumab: Phase 1 readout est. (NCT06824363)
DESCRIPTION:Tremelimumab\, phase 1.\nStudy: ProofPrincip IntraTu TCells Sin
 glDoseImmunCheckpoinInhib Gastro-Esophage Adenocarcinoma w/ARID1a Mu\nEsti
 mated primary completion: January 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06824363
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03601455-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT03601455)
DESCRIPTION:Tremelimumab\, phase 2\, Bladder Cancer.\nStudy: Radiation Ther
 apy and Durvalumab With or Without Tremelimumab in Treating Participants W
 ith Unresectable\, Locally Advanced\, or Metastatic Bladder Cancer\nEstima
 ted primary completion: 31 January 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT03601455
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04499053-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT04499053)
DESCRIPTION:Tremelimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Du
 rvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected
  Patients With Non-small Cell Lung Cancer\nEstimated primary completion: F
 ebruary 2027. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tremeli
 mumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT04499053
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04605731-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270223
DTEND;VALUE=DATE:20270224
SUMMARY:Tremelimumab: Phase 1 readout est. (NCT04605731)
DESCRIPTION:Tremelimumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: Durv
 alumab and Tremelimumab After Radioembolization for the Treatment of Unres
 ectable\, Locally Advanced Liver Cancer\nEstimated primary completion: 23 
 February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tremel
 imumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04605731
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07175441-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT07175441)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Eval
 uation of RBS2418 in Combination With Tremelimumab Plus Durvalumab in Part
 icipants With Advanced Unresectable Hepatocellular Carcinoma\nEstimated pr
 imary completion: April 2027. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/tremelimumab#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07175441
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06855225-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT06855225)
DESCRIPTION:Tremelimumab\, phase 2.\nStudy: A Phase II Study of Single Trem
 elimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin i
 n Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholang
 iocarcinoma\nEstimated primary completion: May 2027. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06855225
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05451043-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT05451043)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Durv
 alumab and Tremelimumab in Combination With Propranolol and Chemotherapy f
 or Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)\nEstimated 
 primary completion: 1 May 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/tremelimumab#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT05451043
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05063565-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT05063565)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Ther
 aSphere With Durvalumab and Tremelimumab for HCC\nEstimated primary comple
 tion: June 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/trem
 elimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT05063565
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04005690-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Tremelimumab: Phase 1 readout est. (NCT04005690)
DESCRIPTION:Tremelimumab\, phase 1.\nStudy: Targeted Pathway Inhibition in 
 Patients With Pancreatic Cancer\nEstimated primary completion: 1 June 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/tremelimumab#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04005690
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06796114-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270625
DTEND;VALUE=DATE:20270626
SUMMARY:Tremelimumab: Phase na readout est. (NCT06796114)
DESCRIPTION:Tremelimumab\, phase na\, Hepatocellular Carcinoma.\nStudy: Ide
 ntification of Innovative Biomarkers to Predict Outcomes in Hepatocellular
  Carcinoma Treated With Tremelimumab and Durvalumab\nEstimated primary com
 pletion: 25 June 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/tremelimumab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06796114
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04522544-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT04522544)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Durv
 alumab and Tremelimumab in Combination With Y-90 SIRT for Intermediate Sta
 ge HCC\nEstimated primary completion: 31 July 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT04522544
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07511504-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT07511504)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Y-90
  Radioembolization\, Durvalumab\, Tremelimumab\, and Zanzalintinib for the
  Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma\n
 Estimated primary completion: 1 August 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07511504
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04169841-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT04169841)
DESCRIPTION:Tremelimumab\, phase 2.\nStudy: Study Evaluating the Efficacy o
 f a Double Immunotherapy Combined With Olaparib in Patients With Solid Can
 cers and Carriers of Homologous Recombination Repair Genes After Olaparib 
 Treatment\nEstimated primary completion: 10 August 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT04169841
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07391670-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Tremelimumab: Phase 1 readout est. (NCT07391670)
DESCRIPTION:Tremelimumab\, phase 1.\nStudy: A Phase I Dose Escalation and D
 ose Expansion Study to Investigate the Pharmacokinetics and Safety of Subc
 utaneous Durvalumab\nEstimated primary completion: 30 August 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/tremelimumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT07391670
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06045975-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20270927
DTEND;VALUE=DATE:20270928
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT06045975)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Durv
 alumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With H
 CC Treated by by Percutaneous Ablation Procedure\nEstimated primary comple
 tion: 27 September 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/tremelimumab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06045975
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05701488-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Tremelimumab: Phase 1 readout est. (NCT05701488)
DESCRIPTION:Tremelimumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: SIRT
  With Tremelimumab and Durvalumab for Resectable HCC\nEstimated primary co
 mpletion: 1 October 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/tremelimumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT05701488
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06526104-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20271001
DTEND;VALUE=DATE:20271002
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT06526104)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Stud
 y of Tremelimumab and Durvalumab (MEDI4736) (T300+D) in Advanced Hepatocel
 lular Carcinomas With Child-Pugh-B Cirrhosis\nEstimated primary completion
 : 1 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tre
 melimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06526104
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07027436-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:Tremelimumab: Phase 3 readout est. (NCT07027436)
DESCRIPTION:Tremelimumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Radi
 ation Therapy Followed by Durvalumab (MEDI4736) and Tremelimumab And Surge
 ry Versus Radiation Therapy Followed by Surgery for Resectable Hepatocellu
 lar Carcinoma.\nEstimated primary completion: 12 October 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/tremelimumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07027436
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06710223-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tremelimumab: Phase 1 readout est. (NCT06710223)
DESCRIPTION:Tremelimumab\, phase 1\, Hepatocellular Carcinoma.\nStudy: Cryo
 ablation and Arterial Infusion of SD-101 in Combination With Durvalumab an
 d Tremelimumab\nEstimated primary completion: December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/tremelimumab#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06710223
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02812420-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Tremelimumab: Phase 1 readout est. (NCT02812420)
DESCRIPTION:Tremelimumab\, phase 1\, Urothelial Carcinoma.\nStudy: Durvalum
 ab and Tremelimumab in Treating Patients With Muscle-Invasive\, High-Risk 
 Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Befo
 re Surgery\nEstimated primary completion: 31 December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/tremelimumab#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT02812420
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02029001-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT02029001)
DESCRIPTION:Tremelimumab\, phase 2.\nStudy: Adapting Treatment to the Tumor
  Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpeci
 ficTreatment\nEstimated primary completion: January 2028. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT02029001
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06880523-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT06880523)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: STRI
 DE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresect
 able Hepatocellular Carcinoma\nEstimated primary completion: 31 January 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/tremelimumab#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06880523
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06911255-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Tremelimumab: Phase 1/2 readout est. (NCT06911255)
DESCRIPTION:Tremelimumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Sa
 fety and Efficacy of Tremelimumab+Durvalumab(MEDI4736)+TACE in Unresectabl
 e Hepatocellular Carcinoma\nEstimated primary completion: 31 March 2028. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/tremelimumab#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT06911255
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05932199-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Tremelimumab: Phase 1/2 readout est. (NCT05932199)
DESCRIPTION:Tremelimumab\, phase 1/2.\nStudy: Neoadjuvant Durvalumab and Tr
 emelimumab With and Without Chemotherapy for Mesothelioma\nEstimated prima
 ry completion: 31 May 2028. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/tremelimumab#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT05932199
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03539822-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Tremelimumab: Phase 1/2 readout est. (NCT03539822)
DESCRIPTION:Tremelimumab\, phase 1/2\, Hepatocellular Carcinoma.\nStudy: Ca
 bozantinib Plus Durvalumab With or Without Tremelimumab in Patients With G
 astroesophageal Cancer and Other Gastrointestinal Malignancies\nEstimated 
 primary completion: 30 June 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/tremelimumab#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT03539822
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04430452-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT04430452)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Durv
 alumab With/Without Tremelimumab After Palliative Hypofractionated Radioth
 erapy for Hepatocellular Carcinoma\nEstimated primary completion: 31 July 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/tremelimumab#up
 coming-events\nRegistry record: https://clinicaltrials.gov/study/NCT044304
 52
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07288034-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20281008
DTEND;VALUE=DATE:20281009
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT07288034)
DESCRIPTION:Tremelimumab\, phase 2\, Non-Small Cell Lung Cancer.\nStudy: Im
 munotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Re
 sponse and Selection of Second-line Treatment in Stage IIIB-IV Non-small C
 ell Lung Cancer\, IMMUNO-BIOMAP Trial\nEstimated primary completion: 8 Oct
 ober 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tremelimum
 ab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 7288034
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03317158-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tremelimumab: Phase 1/2 readout est. (NCT03317158)
DESCRIPTION:Tremelimumab\, phase 1/2\, Bladder Cancer.\nStudy: Modern Immun
 otherapy in BCG-Unresponsive\, BCG-Relapsing and High Risk BCG-Naive Non-M
 uscle Invasive Urothelial Carcinoma of the Bladder\nEstimated primary comp
 letion: 31 December 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/tremelimumab#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT03317158
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04988945-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT04988945)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: TACE
  and SBRT Followed by Double Immunotherapy for Downstaging Hepatocellular 
 Carcinoma\nEstimated primary completion: 31 December 2028. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/tremelimumab#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04988945
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06564623-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Tremelimumab: Phase 1 readout est. (NCT06564623)
DESCRIPTION:Tremelimumab\, phase 1.\nStudy: Targeting Driver Oncogenes With
  a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Bili
 ary Tract Cancers (BTC)\nEstimated primary completion: March 2029. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/tremelimumab#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT06564623
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07168668-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20290814
DTEND;VALUE=DATE:20290815
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT07168668)
DESCRIPTION:Tremelimumab\, phase 2.\nStudy: Partial Immune-boost TACE in un
 rEseCTable HCC Patients Under Systemic Treatment\nEstimated primary comple
 tion: 14 August 2029. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /tremelimumab#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07168668
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06904170-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20290914
DTEND;VALUE=DATE:20290915
SUMMARY:Tremelimumab: Phase 2/3 readout est. (NCT06904170)
DESCRIPTION:Tremelimumab\, phase 2/3\, Hepatocellular Carcinoma.\nStudy: Du
 rvalumab and Tremelimumab With or Without Hepatic Arterial Infusion of Che
 motherapy in Hepatocellular Carcinoma\nEstimated primary completion: 14 Se
 ptember 2029. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tremeli
 mumab#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06904170
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07122089-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20300102
DTEND;VALUE=DATE:20300103
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT07122089)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Eval
 uation of SIRT Followed by Immunotherapy for Treatment of Hepatocellular C
 arcinoma With Portal Vein Thrombosis\nEstimated primary completion: 2 Janu
 ary 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/tremelimuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 122089
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06921785-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20300315
DTEND;VALUE=DATE:20300316
SUMMARY:Tremelimumab: Phase 3 readout est. (NCT06921785)
DESCRIPTION:Tremelimumab\, phase 3\, Hepatocellular Carcinoma.\nStudy: Phas
 e III Study of Rilvegostomig in Combination With Bevacizumab With or Witho
 ut Tremelimumab as First-line Treatment of Hepatocellular Carcinoma\nEstim
 ated primary completion: 15 March 2030. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT06921785
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07489976-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20300401
DTEND;VALUE=DATE:20300402
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT07489976)
DESCRIPTION:Tremelimumab\, phase 2.\nStudy: IIT2025-03-YANG-LIFT-HCC\nEstim
 ated primary completion: 1 April 2030. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/tremelimumab#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07489976
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03847649-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20300430
DTEND;VALUE=DATE:20300501
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT03847649)
DESCRIPTION:Tremelimumab\, phase 2.\nStudy: A Phase II Study of Durvalumab 
 Treatment - Substudy A: In Patients Who Discontinued Prior Checkpoint Ther
 apy Due to Immune Related Toxicity - Substudy B: For Continued Treatment (
 +/- Tremelimumab) of Patients Previously Enrolled to Completed CCTG Studie
 s\nEstimated primary completion: 30 April 2030. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT03847649
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06999707-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT06999707)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Phot
 on Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC\nE
 stimated primary completion: 31 May 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06999707
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06999694-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT06999694)
DESCRIPTION:Tremelimumab\, phase 2\, Hepatocellular Carcinoma.\nStudy: Prot
 on Radiotherapy Plus Tremelimumab/Durvalumab for BCLC Stage B and C HCC\nE
 stimated primary completion: 31 May 2030. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/tremelimumab#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06999694
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06680739-2015@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20320701
DTEND;VALUE=DATE:20320702
SUMMARY:Tremelimumab: Phase 2 readout est. (NCT06680739)
DESCRIPTION:Tremelimumab\, phase 2.\nStudy: Single cEll pRofiling PErsistaN
 ce To ImmuNothErapy\nEstimated primary completion: 1 July 2032. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/tremelimumab#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT06680739
URL:https://assetmemo.bio/drug/tremelimumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
